跳至主要内容
临床试验/JPRN-UMIN000006667
JPRN-UMIN000006667招募中未知

Phase II study of efficacy of letrozole in postmenopausal patients with endocrine-responsive, HER2-negative metastatic breast cancer resistant to exemestane or anastrozole. - SBP-02

Setouchi Breast Comprehensive Support Organaization0 个研究点目标入组 60 人开始时间: 2011年11月4日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
Female

入选标准

  • 未提供

排除标准

  • 1. Patients with active other malignancies.(other simultaneity malignancies and other heterochrony malignancies within 5 years disease-free interval) *Except patients who cured carcinoma in situ or intramucosal carcinoma by local treatment. 2. Patients with brain metastasis with symptom. 3. Patients who confirmed to be unstable angina pectoris, congestive heart failure, myocardial infarction, myocardial infarction, ventricular arrhythmia that need treat within 6 months before register. 4. Patients who confirmed to be uncontrollable hypertension, diabetes when you register. 5. Patients with severe infectious disease. 6. Patients with severe complications 7. Patients who are receiving bisphosphonates for hypercalcemia by malignancy.(Except patients who had receiving bisphosphonates for osteoporosis, bone metastases.) 8. Other patients who were considered by the primary care physician to be inappropriate as subjects of this trial.

研究者

发起方
Setouchi Breast Comprehensive Support Organaization

相似试验